Biofarm (LTS:0HTH) Current Accrued Expense: lei Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HTH Biofarm SA LTS:0HTH
71 GF Score
Price lei0.24
GF Value lei0.15
! 8 Warning Signs
View Full Analysis

What is Biofarm Current Accrued Expense?

Biofarm LTS:0HTH 71 Current Accrued Expense is lei Mil as of Mar. 2026. GuruFocus rates LTS:0HTH with a GF Score™ of 71/100 and a GF Value™ of lei0.15. The stock has 8 warning signs investors should review.

Biofarm's Current Accrued Expense for the quarter that ended in Mar. 2026 was lei Mil.

Biofarm Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Biofarm's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofarm Current Accrued Expense Chart

Biofarm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biofarm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
LTS:0HTH
71GF Score
Biofarm SA LTS:0HTH
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofarm Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of lei Mil mean?
Biofarm (LTS:0HTH) has a Current Accrued Expense of lei Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Biofarm and its competitors.
Is Biofarm's Current Accrued Expense too high?
Biofarm's current Current Accrued Expense is lei Mil. Overall, Biofarm has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Biofarm's Current Accrued Expense compare to ZTS and UTHR?
Biofarm's Current Accrued Expense of lei Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Biofarm and its competitors. Biofarm's current Current Accrued Expense is lei Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Biofarm (LTS:0HTH) has a current Current Accrued Expense of lei Mil. The stock's GF Value™ is lei0.15, compared to a current price of lei0.24 — trading 58% above its estimated fair value. The current Current Accrued Expense is lei Mil. Biofarm's overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Biofarm (LTS:0HTH), the current Current Accrued Expense is lei Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofarm (LTS:0HTH) Overvalued in 2026?

Based on GuruFocus' analysis, Biofarm stock appears to be overvalued. The current stock price of lei0.24 is trading 58% above its estimated GF Value™ of lei0.15.

Key valuation signals for LTS:0HTH:

  • Current Accrued Expense: lei Mil
  • GF Value™: lei0.15 vs. price of lei0.24 (58% above fair value)
  • GF Score™: 71/100 with 8 warning signs

No single metric tells the full story. See the LTS:0HTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofarm Business Description

Other Exchanges BIO:Romania
Address 99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
71GF Score

Get the complete analysis for LTS:0HTH

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei0.24
Price
lei0.15
GF Value